Paper35129409
Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials.
Burgin DJ and 4 others. Expert Opin Investig Drugs, 2022. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials. Papers, record 35129409. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35129409
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteremia | Major topic |
| Methicillin-Resistant Staphylococcus aureus | Major topic |
| Staphylococcal Infections | Major topic |
| Anti-Bacterial Agents | |
| Clinical Trials as Topic | |
| Humans | |
| Staphylococcus aureus |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIA AI000904 | Intramural NIH HHS | United States | ZIAAI000904 | PubMed and NIH |
Source NIH RePORTER
References121
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8067738 | Antibiotic penetration of and bactericidal activity within endothelial cells. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8067738 | PubMed |
| 2 | 22571999 | Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. | J Microbiol Immunol Infect | 2012 | https://conductscience.org/library/papers/22571999 | PubMed |
| 3 | 12491202 | Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. | Clin Infect Dis | 2003 | https://conductscience.org/library/papers/12491202 | PubMed |
| 4 | 21048011 | LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. | J Clin Microbiol | 2011 | https://conductscience.org/library/papers/21048011 | PubMed |
| 5 | 15668859 | Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. | Clin Infect Dis | 2005 | https://conductscience.org/library/papers/15668859 | PubMed |
| 6 | 15898002 | Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. | J Infect Dis | 2005 | https://conductscience.org/library/papers/15898002 | PubMed |
| 7 | 28386776 | Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. | Infect Dis Ther | 2017 | https://conductscience.org/library/papers/28386776 | PubMed |
| 8 | 24046298 | Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. | Clin Infect Dis | 2013 | https://conductscience.org/library/papers/24046298 | PubMed |
| 9 | 27520326 | Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia. | Ann Pharmacother | 2016 | https://conductscience.org/library/papers/27520326 | PubMed |
| 10 | 24884578 | A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. | BMC Infect Dis | 2014 | https://conductscience.org/library/papers/24884578 | PubMed |
| 11 | 6356275 | Rifampin: mechanisms of action and resistance. | Rev Infect Dis | 1983 | https://conductscience.org/library/papers/6356275 | PubMed |
| 12 | 29364906 | A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. | PLoS One | 2018 | https://conductscience.org/library/papers/29364906 | PubMed |
| 13 | 15184410 | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. | J Clin Microbiol | 2004 | https://conductscience.org/library/papers/15184410 | PubMed |
| 14 | 30038042 | Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/30038042 | PubMed |
| 15 | 29408610 | Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial. | Clin Microbiol Infect | 2018 | https://conductscience.org/library/papers/29408610 | PubMed |
| 16 | 20065327 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. | Clin Microbiol Rev | 2010 | https://conductscience.org/library/papers/20065327 | PubMed |
| 17 | 30455229 | Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30455229 | PubMed |
| 18 | 25048851 | Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. | Clin Infect Dis | 2014 | https://conductscience.org/library/papers/25048851 | PubMed |
| 19 | 29378704 | Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29378704 | PubMed |
| 20 | 8613375 | A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. | Infect Immun | 1996 | https://conductscience.org/library/papers/8613375 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42346648 | Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia-Guidelines and Recent Developments. | Medicines (Basel) | 2026 | https://conductscience.org/library/papers/42346648 | PubMed |
| 40661138 | Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40661138 | PubMed |
| 39421990 | Resilience Against Resistance: Exploring Cutting-edge Therapies for Methicillin-resistant Staphylococcus aureus (MRSA). | Curr Med Chem | 2025 | https://conductscience.org/library/papers/39421990 | PubMed |
| 37101261 | Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. | J Biomed Sci | 2023 | https://conductscience.org/library/papers/37101261 | PubMed |
| 36590413 | Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant Staphylococcus aureus infection models in mice. | Front Microbiol | 2022 | https://conductscience.org/library/papers/36590413 | PubMed |
| 36015090 | Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36015090 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| CTSS | 1520 | PubTator's text mining | https://conductscience.org/library/genes/1520 | NCBI Gene |
| GLRX5 | 51218 | PubTator's text mining | https://conductscience.org/library/genes/51218 | NCBI Gene |
| LYZ | 4069 | PubTator's text mining | https://conductscience.org/library/genes/4069 | NCBI Gene |
| MED1 | 5469 | PubTator's text mining | https://conductscience.org/library/genes/5469 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35129409
GET https://conductscience.org/api/papers/v1/35129409/references?page=2